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Abstract
Background: Exercise is an extreme physiological challenge for skeletal muscle energy metabolism and has notable health
benefits. We aimed to identify and characterize metabolites, which are components of the regulatory network mediating
the beneficial metabolic adaptation to exercise.
Methodology and Principal Findings: First, we investigated plasma from healthy human subjects who completed two
independent running studies under moderate, predominantly aerobic conditions. Samples obtained prior to and
immediately after running and then 3 and 24 h into the recovery phase were analyzed by a non-targeted (NT-)
metabolomics approach applying liquid chromatography-qTOF-mass spectrometry. Under these conditions medium and
long chain acylcarnitines were found to be the most discriminant plasma biomarkers of moderately intense exercise.
Immediately after a 60 min (at 93% VIAT) or a 120 min run (at 70% VIAT) a pronounced, transient increase dominated by
octanoyl-, decanoyl-, and dodecanoyl-carnitine was observed. The release of acylcarnitines as intermediates of partial b-
oxidation was verified in skeletal muscle cell culture experiments by probing
13C-palmitate metabolism. Further
investigations in primary human myotubes and mouse muscle tissue revealed that octanoyl-, decanoyl-, and dodecanoyl-
carnitine were able to support the oxidation of palmitate, proving more effective than L-carnitine.
Conclusions: Medium chain acylcarnitines were identified and characterized by a functional metabolomics approach as the
dominating biomarkers during a moderately intense exercise bout possessing the power to support fat oxidation. This
physiological production and efflux of acylcarnitines might exert beneficial biological functions in muscle tissue.
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Introduction
Physical activity has notable health benefits for the general
population and is an economical and efficient intervention for
treating metabolic syndrome and type 2 diabetes [1–3] as well as
for preventing the associated increase in morbidity and mortality.
The adaptation of the skeletal muscle to endurance training can be
described as an increase in the capacity and efficiency to utilize
fuels [4–6], predominantly fat and carbohydrates for the
generation of ATP [7,8]. Furthermore, the working muscle
produces and releases substances during exercise which not only
mediate the adaptation of the muscle, but also improve the
metabolic flexibility of the complete organism leading to adjustable
substrate utilization, e.g. with improved oxidation of fat and
decreased demand for glucose and glycogen [9–11]. Skeletal
muscle secretes peptides and metabolites that participate in the
regulation of whole body glucose and lipid homeostasis. Recently,
the group of BK Pedersen introduced the term myokines for such
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11519cytokines and other peptides that are produced, expressed, and
released by muscle fibers and exert either paracrine or endocrine
effects [12]. The discovery of C16:1n7-palmitoleate as an insulin-
sensitizing lipokine revealed the existence of a network which uses
metabolites to communicate with other organs [13].
Metabolomics approaches encompass the targeted and non-
targeted, comprehensive analysis of metabolites which represent
powerful tools for the investigation of complex metabolic processes
[14–18]. A limited number of metabolomic studies on specific
aspects of exercise in humans, using gas chromatography-time of
flight (TOF) mass spectrometry (MS) have been reported to date,
including effects of strenuous cycling [19], training associated
metabolic changes in professional rowers [20], the effects of
nutritional modification on the metabolome during the recovery
phase [21] and the comparison of urinary pattern of trained and
untrained women by
1H-NMR [22].
Here, we applied a non-targeted (NT-) metabolomics approach
to investigate the changes in plasma metabolite profile immedi-
ately after moderately intense exercise and following 3 h and 24 h
of recovery, to identify exercise-related biomarkers, and to explore
their potential biological function. We studied a profound
metabolic challenge under physiological metabolic conditions in
a study group consisting of young, healthy men. Two groups
completed an exercise protocol of continuous endurance running
on a treadmill for 60 or 120 min at moderate intensity. Using
liquid chromatography-qTOF-mass spectrometry, medium and
long chain acylcarnitines were identified as the most distinct
exercise biomarkers at the different time points with a transient, up
to nine-fold increase immediately after the run. Moreover, we
provide evidence for a positive biological function of extracellular
acylcarnitines on lipid oxidation demonstrated in human myo-
tubes and skeletal muscle tissue.
Results
Standard laboratory parameters of the first study
In the first study, 13 lean, healthy individuals (table 1)
performed a treadmill run for 60 min at a speed which
corresponded to 93% velocity at the individual anaerobic
threshold (VIAT; approx. 75% VO2max) resulting in significantly
increased blood lactate concentrations after 10 min of exercise
performance and thereafter (Table 2), but remaining in a range
typical for moderate, predominantly aerobic exercise [23]. Plasma
somatotropin levels (13.768.2 vs. 1.1361.8 mg/L) and norepi-
nephrine levels (4.2861.37 vs. 1.8860.71 nmol/L) were signifi-
cantly increased after running, while epinephrine, creatine kinase
activity, and cortisol plasma concentrations were not elevated
(Table 2). The significant decrease of cortisol after 3 h of recovery
phase is likely to represent the circadian decline around 1 pm.
Moreover, treadmill running resulted in strongly increased plasma
nonesterified free fatty acids levels (NEFA; 12766392 versus
3956115 mmol/L). Plasma samples of the first study were used for
the NT-metabolomics analyses.
Non-targeted metabolomics analysis using reversed-
phase UPLC-qTOF-MS
The plasma metabolite pattern of the first study group was
analyzed by UPLC-qTOF-MS in the positive ionization mode at
four time points, before the run, immediate afterwards (0 h), 3 h
and 24 h after the run. We constructed a model using partial least
squares-discriminant analysis (PLS-DA) with an orthogonal signal
correction (OSC) data filter using randomized sample ordering,
according to Wold et al. [24]. As indicated by the PLS-DA score
plot, considerable changes of the metabolome in the plasma at
each time point representing more than 2500 metabolite ions per
individual are visible (Figure 1A). To ensure that the calculated
model was reliable and the observed clustering was not due to
chance, we performed an internal validation using 7-fold cross-
validation as described in [25]. The estimated goodness of fit of
R
2Y was 0.926, and the goodness of prediction of Q
2Y was 0.548
which underlines the robustness of the model. To assess the
significance of the predictive ability, a response permutation test (Y
scrambling) was used and showed no overfitting (R
2Y-intercept of
0.490, and Q
2 –intercept of -0.775). Moreover, a clear, distinct
separation was obtained by generation of the OSC-PLS-DA score
plot of the metabolome of the pre-exercise state and immediately
after exercise (Figure 1B).
Identification of metabolites reflecting changes in the
plasma metabolite pattern during exercise and recovery
To mine the complex data and propose which metabolite ion
masses could be of potential interest, we used the S-plot of SIMCA-
P [26]. The S-plot given in Figure 1C shows the m/z values of the
most altered metabolite ions in plasma which are responsible for the
separation of the time points in the PLS-DA score plot in Figure 1A.
The metabolite ions with the greatest influence on the cluster are
located furthest away from the center of the S-plot. The
characterization of the most discriminative plasma metabolite ions
by mass spectrometric fragmentation pattern resulted in the
identification of several medium chain acylcarnitine species namely,
C8:0(octanoyl)-, C10:0(decanoyl)-, C10:1(decenoyl)-, C10:2-OH(-
hydroxy-decadienoyl)- and C12:0(dodecanoyl)-carnitine (Table 3).
Since we used positive ionization for the mass spectrometric
analysis, highly negatively charged metabolites such as fatty acids
could not be detected in our approach.
Identification of the discriminating ion masses responsible for
the clear separation of the resting state and the acute exercise state
(Fig. 1B,D) revealed again that acylcarnitines were the major
metabolite group of exercise-induced biomarkers with increases in
C6:0(hexanoyl)-, C8:0-, C10:0-, C10:1-, C12:0-, and C14:2(tetra-
decadienoyl)-carnitine (Table 4).
Time-course of the acylcarnitine species plasma levels in
the exercise phase and under recovery conditions
The signal intensities (based on the peak height) of all
acylcarnitines detectable in our mass spectrometric data showed
similar kinetics, namely a strong, significant increase immediately
after the exercise bout and a pronounced decrease thereafter
leading to signal intensities similar to the pre-run data, except for
C2:0(acetyl)-, C4:0(iso/butyryl)-, C12:1- and C14:0-carnitine,
which showed no significant changes at any time point
Table 1. Physical characteristic of the subjects.
first exercise study
(n=13)
second exercise study
(n=8)
Mean SE mean SE
Age (yrs) 32.6 66.1 30.9 65.8
Body mass index (kg6m
2) 21.6 61.2 21.8 61.2
VO2 max (ml/kg/min) 56.5 61.4 63.0 62.0
VIAT (km/h) 14.0 60.6 15.1 61.0
VIAT - velocity at individual anaerobic threshold,
VO2max - maximal oxygen consumption.
doi:10.1371/journal.pone.0011519.t001
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presented in Figure 2B for each individual runner.
As we applied a non-targeted approach, the measured signals
are only relative intensities. We verified the acylcarnitine kinetics
quantitatively in a second exercise study. Here, the treadmill run
lasted over 120 min at a lower intensity of 70% VIAT. Accordingly,
blood lactate concentrations were not significantly increased after
the run (1.4960.66 vs. 1.2360.37 mmol/L before run), while the
increase in NEFA levels was comparable (8726407 vs.
112678 mmol/L). Blood samples in the first study were drawn
Table 2. Concentrations of conventional clinical chemical plasma parameters at different time points of the first exercise study.
pre-run 0 h (immediately after) run 3 h after run 24 h after run
NEFA (mmol/L) 3956115 12766392 * 3306254 2826142
Cortisol (nmol/L) 6246154 6926232 3446106 * 6026104
Somatotropin (mg/L) 1.1361.8 13.768.2 * 0.160.09 0.0560.1
Creatine kinase (U/L) 2256148 2686156 2666158 2346147
Epinephrine (nmol/L) 0.3160.20 0.4160.29 0.3360.18 0.3360.19
Norepinephrine (nmol/L) 1.8860.71 4.2861.37 * 2.3861.09 2.4360.78
Lactate (mmol/L) 0.9160.37 (1.6360.47 *)
a)
2.0860.86 *
Nd nd
Values are shown as mean 6 SE.
a)measured after 10 min of treadmill performance.
*p,0.05 vs. pre.
nd=not determined.
doi:10.1371/journal.pone.0011519.t002
Figure 1. Identification of metabolites reflecting changes in the metabolite pattern during moderate intensity exercise and
recovery. Comparison of the time-dependent changes in the plasma metabolome of 13 individuals after a 60 min treadmill run at 93% velocity at
individual anaerobic threshold (VIAT; approximately 75% of VO2max), showing the metabolome at rest, immediately at the end of the physical activity
and at two time points in the recovery phase. The analyses were performed by partial least squares-discriminant analysis (PLS-DA) and OSC-filtering.
(A) OSC-filtered PLS-DA score plot showing pre-run (&), immediately after run (#), three hours after run (D) and 24 hours after run (*); (B) OSC-
filtered PLS-DA score plot showing pre run (&) and immediately after run (#). (C,D) The corresponding S-plot to (A) and (B), respectively. The
variables are labelled with m/z values. Potential metabolic biomarkers including the corresponding m/z values are presented in Table 3 and Table 4.
doi:10.1371/journal.pone.0011519.g001
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second investigation resting blood samples were collected following
the assessment of IMCL by magnetic resonance spectroscopy, i.e.
1 h 45 min after a standardized breakfast. Despite these
differences in study design, the kinetics of the absolute plasma
concentrations of the acylcarnitines in the second study were
completely comparable with the time courses found in the first
study group (Fig. 2C). The sum of C8:0, C10:0, and C12:0-
carnitine in the second study increased from 0.22 mmol/L before
to 1.34 mmol/L immediately after the run. Determination of
intramyocellular lipids revealed a significant decrease in intracel-
lular lipid stores of soleus (reduction of 2268%) and tibialis
anterior muscles (reduction of 24616%; data not shown),
suggesting that intramyocellular lipids were at least partially
metabolized during the 120 min treadmill run.
13C-acylcarnitine synthesis and release from human
myotubes
To obtain direct proof that the working skeletal muscle could be
the source of the elevated acylcarnitine concentrations in the
plasma, we studied the time course of acylcarnitine metabolites
derived from
13C-palmitate upon incubation with primary human
myotubes. Intracellular and released acylcarnitines were deter-
mined by UPLC-qTOF-MS. After 30 min, 4 and 20 h of
incubation with
13C-palmitate intracellular
13C-palmitoyl-carni-
tine was clearly present (Fig. 3A). After 4 and 20 hours of
13C-
palmitate incubation
13C-palmitoyl-carnitine was also detectable
extracellularly (Fig. 3B), and
13C-derivates of C12:0 and C10:0
carnitine were found after 20 h in the supernatant (Fig. 3 C,D).
These data provide clear evidence that primary human myotubes
rapidly metabolize palmitate to palmitoyl-carnitine, which is
released in the supernatant together with C12:0- and C10:0-
carnitine resulting from partial oxidation of palmitate. We did not
detect other acylcarnitine species.
Effects of acylcarnitines on fatty acid oxidation in primary
human skeletal muscle cells and soleus, extensor
digitorum longus, tibialis and quadriceps muscles of
mice
To study the potential effect of medium chain acylcarnitines on
fatty acid metabolism, human myotubes were incubated with an
equimolar mixture of C8:0-, C10:0- and C12:0-carnitines (in the
following referred to as (C8-12:0) carnitines). Comparison of
palmitate oxidation in the presence of 10 or 100 mM L-carnitine,
acetyl-carnitine or (C8-12:0) carnitines revealed that the medium
chain acylcarnitines were most efficient in supporting b-oxidation
(Fig. 4A), with C12:0 carnitine being more potent than C10:0- and
C8:0-carnitine (Fig. 4B). When we performed palmitate oxidation
in the presence of 50 mM L-carnitine and added increasing
concentrations of (C8-12:0) carnitine we found a slight, but
significant increase in fatty acid oxidation even in the presence of
1 mM of medium chain acylcarnitines (Fig. 4C), which is close to
the detected physiological plasma concentration of 1.34 mMo f
(C8-12:0) carnitine after the run. The additional effect of 10 or
100 mM (C8-12:0)-acylcarnitine (Fig. 4C), which may reflect local
extracellular concentrations in skeletal muscle under exercise
conditions, was comparable to the difference in palmitate
oxidation between equimolar concentrations of L-carnitine and
(C8-12:0)-acylcarnitine in figure 4A. To further verify the
activation of palmitate oxidation in entire muscle, the effect of
100 mM (C8-12:0)-acylcarnitines was studied ex vivo in oxidative
soleus muscle as well as in glycolytic extensor digitorum longus,
tibialis and quadriceps muscles from mice. A comparable increase
of palmitate oxidation as detected in human myotubes was found
(Fig. 4D) supporting a physiological function of the (C8-12:0)-
carnitines in skeletal muscle.
Gene expression in primary human skeletal muscle cells
after treatment with acylcarnitines
One effect of acylcarnitines regulating fatty acid metabolism in
human myotubes could be altered expression of key regulators of
fatty acid transport or oxidation or lipolysis. We compared the
effect of 100 mM (C8-12:0)-acylcarnitine with 100 mM L-carnitine,
60 mM palmitate and the combination of acylcarnitine and
palmitate on the expression of peroxisome proliferator activated
receptor-c coactivator (PGC)-1a, carnitine palmitoyltransferase
(CPT)1b, CD36, cytochrome c oxidase subunit I (COX1), and
angiopoietin-like (AngPL)-4 after 1, 3, 8 and 20 h of treatment.
After short term incubation for 1 or 3 h we found no effects of
Table 3. Most influential metabolites contributing to the
separation of the clusters of the exercise and recovery phase
shown in Figure 1A.
retention
time mass (m/z) Metabolite
p-value
(ANOVA)
15.83 432.3 Glycochenodeoxycholic acid* 0.066
19.59 337.2 Unidentified 0.006
6.62 105.0 Hippurate 0.014
12.48 288.2 C8:0 carnitine 0.001
14.30 314.2 C10:1 carnitine ,0.001
14.30 315.2 isotope of 314.2 ,0.001
15.42 328.2 C10:2-OH carnitine 0.002
15.60 316.2 C10:0 carnitine ,0.001
15.60 317.2 isotope of 316.2 ,0.001
18.76 344.2 C12:0 carnitine ,0.001
Only metabolites showing significant changes are given.
*mass (m/z) represents a fragment of this metabolite.
doi:10.1371/journal.pone.0011519.t003
Table 4. Most influential metabolites contributing to the
separation of the clusters of the exercise and pre run phase
shown in Figure 1C.
retention
time
mass
(m/z) Metabolite
immediately after
run vs. pre run
p-value
(t-test)
6.62 105.0 Hippurate q 0.054
8.94 260.1 C6:0 carnitine q 0.010
12.48 288.2 C8:0 carnitine q 0.019
12.48 289.2 isotope of 288.2 q 0.019
14.30 314.2 C10:1 carnitine q 0.001
14.30 315.2 isotope of 314.2 q 0.001
15.60 316.2 C10:0 carnitine q ,0.001
15.60 317.2 isotope of 316.2 q ,0.001
18.38 368.2 C14:2 carnitine q 0.01
18.76 344.3 C12:0 carnitine q 0.012
19.59 337.2 Unidentified Q 0.008
Only metabolites showing significant changes are given.
doi:10.1371/journal.pone.0011519.t004
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increase in PGC-1a expression was detected (Fig. 5A). The
induction of CPT1, CD36, COX1 and AngPL-4 expression by
palmitate was not influenced by acylcarnitines (Fig. 5B–E), while
acylcarnitines alone decreased AngPL-4 expression (Fig. 5E).
Thus, the mRNA expression data could not explain the effect of
acylcarnitines on palmitate oxidation.
Discussion
In our exercise studies under moderate intensity, predominantly
aerobic conditions we found an up to nine-fold increase in
medium chain and long chain acylcarnitines immediately after
running, which decreased very rapidly in the recovery phase. The
major findings are: firstly, medium chain C8:0-, C10:0-, and
Figure 2. Time-course for the acylcarnitine species plasma levels during the exercise phase and under recovery conditions. (A) Time-
dependent changes of acylcarnitine species during the exercise bout and in the recovery phase, based on non-targeted (NT-)metabolomics signal
intensity data. The relative amounts of acylcarnitines are based on peak heights. Values are means 6SE. *p,0.05, significantly different from the pre
run signal intensity; (n=13). (B) Time-dependent changes of 13 individual C10:0 carnitine levels based on NT-metabolomics data. (C) Quantitative
analysis of time-dependent changes of plasma acylcarnitine concentrations investigated in eight individuals performing a continuous 120 min
treadmill run at 70% VIAT in an independent second exercise study. Values are means 6SE. *p,0.05, significantly different from the pre-run
concentrations. As a C8- instead of a C18-reversed phase UPLC-column was used to achieve the detection of the long-chain C16 (palmitoyl)-carnitine,
the analysis of C2:0-carnitine was not possible in this experiment.
doi:10.1371/journal.pone.0011519.g002
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metabolite pattern immediately after exercise vs the pre-exercise
state; secondly, primary human skeletal muscle cells can produce
and release acylcarnitines using palmitate as a substrate; and
thirdly, C8:0-, C10:0-, and C12:0-carnitine support palmitate
oxidation in skeletal muscle cells and muscle tissue.
The identification of exercise-related biomarkers with metabolic
properties is key to understanding the beneficial effects of physical
activity. In our non-hypothesis-driven metabolic profiling ap-
proach within more than 2500 metabolite ions per individual, we
found that medium and long chain acylcarnitines are the most
discriminating exercise-related metabolites under the applied
physiological and analytical conditions. The specific and marked
elevation of medium and long chain acylcarnitine pattern was
dominated by C8:0-, C10:0-, and C12:0-carnitine. Since a
pronounced decrease of plasma acylcarnitine levels during an
oral glucose tolerance test was recently reported suggesting that
food intake results in decreased acylcarnitine levels [16], breakfast-
related effects can be exclude in our studies. However, in the
recovery phase it is quite likely that not only the end of the exercise
activity but also the food consumption thereafter could be involved
in the decline of acylcarnitines.
The exercise-related increase in plasma acylcarnitine concentra-
tions in humans had first been described in the 1980s and early
1990s [27–30]. Interestingly, after high-intensity or exhaustive
exercise with marked plasma lactate concentrations above 5 mM
plasma acylcarnitine concentrations failed to increase, while
elevated acetylcarnitine levels were found [27,28]. We found in
both studies with moderate exercise intensities and only slight or no
detectable increases in plasma lactate pronounced increase in
acylcarnitines, while acetylcarnitine did not change significantly.
Since the major source of acetylcarnitine is acetyl-CoA formed from
pyruvate oxidation [31], increases in acylcarnitines during exercise
may indicate high rates of fatty acid oxidation and low reliance on
glycolysis, which is supported by the moderate or lacking increase in
lactate in our studies. Since based on methodological limitations in
the 1980s and 1990s acylcarnitines had only been described as the
difference between total and free carnitine [29,30] or as short chain
(#10 carbons)- and long-chain (.10 carbons)-carnitines [27,28].
The specification of medium chain acylcarnitines as exercise-
increased biomarkers was not possible in these earlier studies.
The working muscle has always been considered as the source of
acylcarnitines found in plasma during exercise conditions [28–30],
and intramuscular acylcarnitine accumulation has been demon-
strated in conditions of increased muscle fat oxidation [32]. In the
present study we provide direct evidence for the ability of primary
human myotubes to produce and release acylcarnitines from
palmitate, indicating incomplete oxidation of this fatty acid. Our
Figure 3.
13C-Acylcarnitine synthesis and release from primary human myotubes. Comparison of the time course of intracellular (A) and
extracellular (B) intensity levels of
12C- and
13C-palmitoyl-carnitine in an experiment with primary human myotubes incubated with a mixture of
125 mM [U-
13C16]palmitate/125 mM palmitate for 30 min, 4 h and 20 h. (C) The time course of the
12C- and
13C-signal intensity of dodecanoyl-
carnitine and (D) decanoyl-carnitine. The
13C-signal of the respective acylcarnitine is marked by a dash dotted arrow, the
12C-signal by a solid arrow.
doi:10.1371/journal.pone.0011519.g003
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24 h load of human myotubes with 1000 mM fatty acids and
carnitine increases production and efflux of acylcarnitines [33].
The formation of acylcarnitines may serve as a ‘‘buffer’’ for the
limited and metabolically important CoA pool [27], and has been
viewed as a detoxifying system that permits mitochondrial efflux of
Figure 4. Effects of acylcarnitines on fatty acid oxidation in primary human skeletal muscle cells as well as soleus, extensor
digitorum longus, tibialis and quadriceps muscles from mice. Oxidation of
3H-palmitate determined after 4 h in human myotubes in the
presence of L-carnitine (L-C), acetylcarnitine (ActC), an equimolar mixture of C8:0-, C10:0- and C12:0-acylcarnitine (AC), or C8:0-(C8-AC), C10:0- (C10-
AC) and C12:0-acylcarnitine (C12-AC) as indicated (A,B). Values of
3H-palmitate oxidation of control cells were set as 1. (C) Palmitate oxidation in the
presence of 50 mM L-carnitine and 1, 5, 10 or 100 mM AC. Values of
3H-palmitate oxidation of cells solely incubated with 50 mM L-carnitine were set as
1; shown are means 6 SEM from 4 independent experiments, * p,0.05 vs. L-carnitine; # p,0.05 vs acetyl-carnitine; { p,0.05 vs. C8-AC or C10-AC,
respectively. (D) Oxidation of
3H-palmitate in mouse soleus, extensor digitorum longus (EDL), tibialis (tib) or quadriceps (Q) muscle from three
different mice determined after 90 min in the presence of an equimolar mixture of C8:0-, C10:0- and C12:0-acylcarnitine as indicated. Shown are
means 6 SEM, values of
3H-palmitate oxidation in untreated tissues were set as 1, * p,0.05 vs. untreated tissues.
doi:10.1371/journal.pone.0011519.g004
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tines in blood and urine, well known from inborn mitochondrial
diseases [35,36]. Plasma acylcarnitines were also increased in high
fat diet-induced obesity in animal models [32,33] and in obese
and type 2 diabetic humans [37], suggesting that efflux of
acylcarnitines occurs when the influx of acyl-CoA into mitochon-
dria exceeds the capacity for complete oxidation of the fatty acids
due to chronic oversupply with substrate. However it is important
to note that increased availability of substrates for b-oxidation is
also a physiological phenomenon associated with the high
lipolytic rates found during exercise or starvation, subsequently
resulting in acute efflux of acylcarnitines into plasma depicted as
total esterified carnitines [29,30] or total long chain acylcarnitines
[38].
What we believe is one major finding of the present study is the
induction of higher rates of palmitate oxidation in primary human
myotubes and soleus, extensor digitorum longus, tibialis and
quadriceps muscle from mice in the presence of extracellular
C8:0-, C10:0-, and C12:0-carnitine. In muscles from mice
stimulation of palmitate oxidation is greatest in murine soleus
muscle which is predominantly type I fibers (oxidative) and least in
EDL which is primarily type IIb (glycolytic) fibers. This finding
would be the predicted result if the effect of medium-chain
acylcarnitines is primarily via its impact on oxidative metabolism.
Free carnitine availability has been considered to be the limiting
factor for muscle fat oxidation for decades and manipulating the
L-carnitine pool in the muscle by dietary regiments is still the focus
of scientific and commercial approaches to enhance b-oxidation
[33]. Of note, the direct comparison of the effect of C8:0-, C10:0-,
and C12:0-carnitine and L-carnitine on palmitate oxidation
revealed higher rates of palmitate oxidation in the presence of
acylcarnitines. In this experimental setting, human myotubes were
not incubated with additional L-carnitine which raises the question
of the physiological relevance of this finding. Plasma levels of free
Figure 5. Gene expression in primary human skeletal muscle cells after treatment with acylcarnitines. mRNA expression of PGC-1a (A),
CPT1b (B), CD36 (C), COX1 (D) and AngPL-4 (E) related to b-actin mRNA levels after incubation with 100 mM L-carnitine (L-C), an equimolar mixture of
C8:0-, C10:0- and C12:0-acylcarnitine (total 100 mM; AC), 60 mM palmitate (p), or p and AC as indicated. Values are shown as fold changes compared
with untreated (L-C, AC) or BSA-treated (p, p+AC) control cells, shown are means 6 SEM; * significant increase with p,0.05 vs. control cells, { p=0.06
vs. control cells; # significant decrease with p,0.05 vs. control cells. The broken black line indicates the 1-fold expression in control cells.
doi:10.1371/journal.pone.0011519.g005
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moderate intensity exercise [27,28,30]. Thus one could argue
that the myotubes are in a state of L-carnitine deficiency, and
providing L-carnitine during palmitate oxidation clearly increased
fatty acid oxidation. But, the effect of equimolar concentrations of
medium chain acylcarnitines on palmitate oxidation was even
stronger. Moreover, when palmitate oxidation was performed with
physiological concentrations of L-carnitine (50 mM) and acylcar-
nitines (1 mM) we found a slight, but significant effect on fatty acid
oxidation. Therefore we assume that one biological function of
medium chain acylcarnitines could be to support lipid oxidation
during exercise. In addition, since during exercise skeletal muscle
free carnitine content is reduced to approximately 25%, it could be
speculated that the working muscle in vivo might also be in a state
of L-carnitine deficiency [27,31,39].
How can medium chain acylcarnitines support oxidation of
palmitate? It is possible that the transport rate of acylcarnitines
into the cell is higher than the rate for L-carnitine, which is
saturated in the basal state. The Km for carnitine of the organic
cation transporter OCTN2 is in the low mmolar range (4.3 mMi n
vitro; [40]). Acylcarnitines have the potency to inhibit the
transport of L-carnitine by OCTN2 with a more pronounced
effect with increasing chain length [41,42]. Since the increasing
effect of acylcarnitines on palmitate oxidation also depends on the
length of the acyl-moiety with C12 being more effective than C10
and C10 more than C8, it could be speculated that the acylgroup
facilitates the transport of carnitine across the cell membrane
although it needs to be confirmed whether OCTN2 is the
responsible transporter. Moreover, acylcarnitines can enter the
mitochondria directly via carnitine acylcarnitine translocase [43]
without the need for activation by acyl-CoA synthetase (ACS) or
the the carnitine transporter system with CPT1 as the major site of
control of lipid oxidation. Once inside the mitochondrial matrix,
acylcarnitines are transesterified back to free carnitine and the
corresponding acyl-CoA in a reaction catalysed by CPT2. This
may lead to an increased ATP production since they bypass the b-
oxidation enzymes specific for LCFAs and are directly metabo-
lized via medium chain acyl-CoA dehydrogenase followed by the
TCA-cycle. This increase in ATP may favour the ACS-catalyzed
reaction relevant for the activation of palmitate [44]. As outlined
above, the release of free carnitine in the CPT2-catalyzed reaction
may increase the carnitine pool supporting the CPT1-catalyzed
formation of palmitoyl-carnitine, thereby increasing the flux of
palmitate into the mitochondria.
The concept that medium chain acylcarnitines per se act as
signalling molecules thereby activating pathways involved in
increased b-oxidation can also not be excluded. Acetyl-carnitine
at high concentration (1 mM) has been shown to activate AMP-
activated kinase [45]. We found slight increases in PGC-1a
expression by medium chain acylcarnitines, which might indicate
activation of AMPK. However, we could not detect increased
phosphorylation of AMPK or its substrate acetyl-CoA carboxylase
after treatment with medium chain acylcarnitines in our cell
culture experiments with primary human myotubes (data not
shown). Thus the signalling properties of acylcarnitines remains
speculative, but the fact that acylcarnitines can bind to
phospholipid bilayers, as do other amphipathic lipids, and thereby
alter the function of membranes or membrane-bound proteins is
also worth taking into consideration [46].
In conclusion, increased plasma levels of medium chain
acylcarnitines are not only dominating biomarkers of moderate
intensity exercise, one of the most important and successful
interventions for improving health benefits, but might be also
biologically active molecules enhancing b-oxidation.
Materials and Methods
Ethics Statement, subjects and study design
The protocol (74/2004) was approved by the Institutional Review
Board of the University of Tuebingen, Schleichstr. 8, 72076
Tuebingen (board chairman: Prof. Dr. D. Luft) according to the
Declaration of Helsinki, and all subjects gave written informed
consent before the study commenced. The investigation was
conducted inaccordance with the ethical principles of Good Clinical
Practice. A total of twenty-one healthy male subjects gave informed
consent to participate in the study. All subjects had to participate ina
preliminary testing procedure one week prior to the main exercise
tests. Running velocity at the individual anaerobic threshold (VIAT)
was determined with an incremental exercise test (start 6 km?h
21,
increment 2 km?h
21 every 3 min) on the treadmill (Saturn, HP
Cosmos, Traunstein, Germany) (Table 1). VIAT was assessed as
described by [47]. Maximal oxygen consumption (VO2max)w a s
assessed during an additional ramp test (start 8 km?h
21 increment
1k m ?h
21 every 0.5 min) until exhaustion [48].
In the first exercise experiment, thirteen of them were subjected
to a 60 min continuous run of moderate intensity. Treadmill speed
was adjusted to 93% of the VIAT as assessed in the preliminary
testing procedure. This corresponds to approximately 75% of
VO2max. Resting blood samples (pre-run) were drawn in sitting
position after an overnight fasting period at 8:15 am. Immediately
after blood sampling, the subjects received a standardized breakfast
(two small bread rolls; total energy content 225 kcal) and exercise
was started at 9:15 am. Further blood samples were drawn in sitting
position immediately (0 h), 3 and 24 h after the end of the exercise
bout. In a second investigation eight subjects completed a 120 min
continuous treadmill run at a running velocity of 70% of the
VIAT(corresponding to approximately 55% VO2max). Here, resting
blood samples were drawn in sitting position direct before the run
which began after the measurement of intramyocellular lipids by
MRS (see below), i.e. 1 h 45 min after a standardized breakfast (two
small bread rolls; total energy content 225 kcal). In the recovery
phase food consumption was not restricted in both studies.
Plasma parameters
Glucose, total nonesterified fatty acids (NEFA) and creatine
kinase activity (CK) were measured by the ADVIA 1650 clinical
chemical analyzer; cortisol and somatotropin were analyzed with
the ADVIA Centaur immunoassay system (both Siemens Health-
care Diagnostics, Fernwald, Germany). The concentrations of
epinephrine and norepinephrine were determined by HPLC using
an analytical kit (Chromsystems, Munich, Germany). Capillary
blood for lactate measurements was obtained from the earlobe and
measured with the EBIO system (Eppendorf, Hamburg, Ger-
many).
Determination of intra-myocellular lipids (IMCL) by
magnetic resonance spectroscopy
Localized image guided proton magnetic resonance spectra of the
tibialisanteriormuscleand thesoleusmusclewereacquiredona1.5-
Tesla whole body imager (Magnetom Vision, Siemens, Erlangen,
Germany). For volume selection, a single voxel STEAM technique
was applied. Measurement parameters were: echo time =10
msec, repetition time =2 sec, volume of interest 11611620 mm
3,
40 acquisitions. IMCL were quantified as previously described
[49].
Cell culture experiments
Human primary skeletal muscle cells were cultured and
differentiated as previously described [50]. To study the
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incubated with 125 mM [U-
13C16]palmitate (99 atom %
13C) and
125 mM palmitate for 30 min, 4 h and 20 h in a-MEM containing
5.5 mM glucose and 2% fetal bovine serum.
For palmitate oxidation, myotubes were incubated in a-MEM
containing 5.5 mM glucose, 0.1% fatty-acid free BSA, 2 mCi/ml
[9,10-
3H(N)]-palmitate (PerkinElmer, Rodgau-Ju ¨gesheim, Ger-
many) and 60 mM unlabelled palmitate for 4 h. L-carnitine,
acetylcarnitine or an equimolar mixture of C8:0-, C10:0- and
C12:0-carnitines (in the following referred to as (C8-12:0)
acylcarnitines) was added as indicated. For palmitate oxidation
in muscle tissue, muscles were removed immediately after
decapitation of mice and incubated for 90 min at 37uC in the
presence or absence of (C8-12:0)-carnitines as described above.
Production of tritiated water was measured after solid-phase
extraction of the supernatant using Oasis HLB cartridges (Waters,
Milford, MA) in a scintillation counter.
RT-PCR and Real-time quantitative PCR analysis
For RNA expression, myotubes were incubated in a-MEM
containing 5.5 mM glucose and palmitate, L-carnitine and
acylcarnitines were added as indicated. Reverse transcription of
total RNA (1 mg) was performed in a volume of 20 ml using
random hexamers and Avian Myeloblastosis Virus reverse
transcriptase with the First strand cDNA synthesis kit for RT-
PCR (Roche, Mannheim, Germany). Aliquots (2 ml) of the reverse
transcription reactions were then submitted in duplicate to online
quantitative PCR with the Light Cycler system (Roche, Mann-
heim, Germany) with SYBRH green using the FastStart DNA-
MasterSYBR Green I (Roche, Mannheim, Germany). The
following primer pairs were used: human PGC-1a sense:
tgtggaactctctggaactg, antisense: tgaggacttgctgagtggt, product of
232 bp; human CPT1b sense: ctcctttccttgctgaggtg; antisense:
tctcgcctgcaatcatgtag, product of 177 bp; human CD36 sense:
ctaatgccagttggagacct, antisense: actgtgaagttgtcagcctc, product of
335 bp; human AngPL-4 sense: agcatctgcaaagccagttt, antisense:
gcgcctctgaattactgtcc, product of 278 bp; human COX1 sense:
ggcctgactggcattgtatt, antisense: tggcgtaggtttggtctagg, product of
177 bp; human b-actin sense: gagcaagagaggcatcctca, antisense:
agcctggatagcaacgtaca, product of 238 bp. The PCR was per-
formed in a volume of 20 ml: 2 ml FastStart DNA-MasterSYBR
Green I, MgCl2 4 mmol/l, and primers according to a primer
concentration of 1 mmol/l. The instrument settings were: After
denaturing at 95uC for 10 minutes, cycling was performed by
denaturing at 95uC for 15 s, annealing at 65uC for 10 s,
elongation for 10 s for PGC-1a, the number of cycles was 45;
annealing at 68uC for 10 s, elongation for 13 s for CPT1b, the
number of cycles was 45; annealing at 64uC for 10 s, elongation
for 14 s for CD36, the number of cycles was 45; annealing at 68uC
for 10 s, elongation for 11 s for AngPL-4; the number of cycles
was 45; annealing at 55uC for 10 s, elongation for 10 s for COX1,
the number of cycles was 50; annealing at 67uC for 10 s,
elongation for 11 s for b-actin, the number of cycles was 40.
UPLC-qTOF-MS analysis
Sample preparation for UPLC-qTOF-MS analysis.
Plasma samples were prepared as described elsewhere [51] and
cell culture supernatants accordingly. For cell lysates, cells were
trypsinized, lyzed, deproteinized with acetonitrile, run to dryness
in a vacuum centrifuge, stored at 220uC, and reconstituted in
150 ml acetonitrile and water (8:2). The quantitative analysis of
acylcarnitine-species in plasma was performed by the addition of
isotope labeled internal standards ([8,8,8
2H3] octanoyl-L-
carnitine, [10, 10, 10
2H3] decanoyl-L-carnitine and [12, 12, 12
2H3] dodecanoyl-L-carnitine (Organic Synthesis Unit, VU
Medical Center, Amsterdam; The Netherlands) to the samples.
Standard curves were established using plasma added isotope label
standard at concentrations from 0.01 to 1 nmol/ml.
UPLC analysis
The chromatographic separation of plasma from the first
exercise study was performed on a 10062.1 mm ACQUITY
1.7 mm/C18 column using an ACQUITY-UPLC system (Waters
Corp, Milford, USA). The column was maintained at 30uC and
the gradient program at a flow rate of 0.25 ml/min was 100% A
(0.1% formic acid in water) for 1 min, changed to 100% B
(acetonitrile) linearly within 30 min and held for 4 min, finally
back to 100% A. Plasma samples from the second study as well as
skeletal muscle cell lysates and supernatants were investigated
using a 10062.1 mm ACQUITY 1.7 mm/C8 column maintained
at 35uC applying a gradient program at a flow rate of 0.35 ml/min
starting with 90% A (0.1% formic acid in water) for 0.5 min,
changed to 100% B (acetonitrile) linearly within 24 min and held
for 4 min, finally back to 90% A.
Mass spectrometric procedures and data collection
The UPLC system was coupled to a Micromass qTOF-MS
(Manchester, UK) equipped with an electrospray source operating
in positive ion mode (full scan mode from m/z 100-650) adjusted to
the following settings: source temperature 120uC, cone gas flow of
50 l/h, desolvation gas temperature 300uC, desolvation gas flow of
500 l/h, capillary voltage 3100 V, cone voltage to 35 V, scan time
0.4 s (using inter-scan delay of 0.1 s), and collision energy 4 eV
(collision gas: argon). All analyses were acquired using the lock
spray to ensure accuracy and reproducibility. Leucine enkephalin
was used as the lock mass (lock spray frequency: 20 s). Potential
biomarkers were identified following our recently published
analytical strategy for the identification of biomarkers in
metabolomics studies, described in detail in [51].
Mass spectra were digitally analyzed using the Micromass
MarkerLynx Applications Manager version 4.0 (Waters Ltd). The
statistical calculation was performed using the intensity of the
metabolite ions. The data were combined into a single matrix by
aligning peaks with the same mass-retention time pair together
from each data file in the data set. The intensity for each peak was
normalized to the sum of the peak intensities for each data set to
enable the comparison of the relative mass intensities of
metabolites between the different data files.
Data analysis
The pre-processed UPLC-qTOF-MS data were exported into
Soft Independent Modeling of Class Analogy (SIMCA)-P (version
11.0, Umetrics AB, Umea, Sweden) for analysis and visualization
by multivariate statistical methods. The ‘‘80% rule’’ [52,53] was
used to remove missing values, the variables having more than
80% non-zero measurement value in one or more of the groups
were kept in the peak list. In total 2543 variables were merged to
the matrix for the following data analysis. Furthermore, after
Pareto scaling and OSC-filtering according to Wold et al. [24],
partial least squares-discriminant analysis (PLS-DA) was applied.
The S-plot was used to identify metabolites exerting a major
influence on the group membership [26]. The predictive ability of
the model was assessed by internal validation using 7-fold cross-
validation and response permutation testing. Clinical chemical,
anthropometric data of the individuals and cell culture experi-
ments were computed using the statistical software packet JMP
(SAS Institute, Inc., Cary, NC). p,0.05 was considered signifi-
cant.
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